An innovative new approach to the treatment of inflammatory diseases such as Alzheimer’s and NASH
The start-up, IPCure, and Erganeo have signed a licence agreement for the exclusive exploitation of a new type of compounds for the treatment of certain diseases with an inflammatory component.